Volume : 09, Issue : 12, December – 2022
Title:
94.SIMULTANEOUS ESTIMATION OF TIMOLOL MALEATE AND DORZOLAMIDE HYDROCHLORIDE IN AS API AND IN OPHTHALMIC SOLUTION DOSAGE FORM BY RP-HPLC
Authors :
K.Anusha, D.Rajkumar
Abstract :
A fast, sensitive and accurate reverse phase liquid chromatographic method was developed and validated for the simultaneous determination of Dorzolamide and Timolol maleate in ophthalmic preparations. Chromatographic separation was achieved on Inertsil ODS 3V C18 column (250 X 4.6 mm, 5 µm particle size) with mobile phase consisting of Acetonitrile and 1-Octane Sulphonic acid buffer (0.02M) pH adjusted to 3.5 ± 0.05 with o-phosphoric acid (36:64 V/V) at a flow rate of 1.0 mL/min. The analytes were detected at 254 nm and 295 nm for Dorzolamide and Timolol maleate respectively by PDA detector. Brimonidine was used as internal standard (IS). The retention time of Dorzolamide, Timolol maleate and Brimonidine were found to be at 6.020 ± 0.02, 8.254 ± 0.01 and 4.636 ± 0.01 mins respectively. The linearity of the method ranged between 4-720 and 1-180 µg/mL for Dorzolamide and Timolol maleate respectively with correlation coefficient 0.999 for both the drugs in binary mixture. The LOD was found to be 0.6951 µg/mL and 0.2489 µg/mL for Dorzolamide and Timolol maleate respectively and LOQ was found to be 2.3214 µg/mL and 0.8317 µg/mL for Dorzolamide and Timolol maleate respectively.
Keywords: Dorzolamide, Timolol maleate, RP‐HPLC, Simultaneous estimation.
Cite This Article:
Please cite this article in press K.Anusha et al, Simultaneous Estimation Of Timolol Maleate And Dorzolamide Hydrochloride In As Api And In Ophthalmic Solution Dosage Form By RP-HPLC.., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
:
1. FDA Approved Drug Products: TRUSOPT (dorzolamide hydrochloride) ophthalmic solution
2. Arieta C, Amaral M, Matuda E, Crosta C, de Carvalho Moreira Filho D, Jose N: Dorzolamide X apraclonidine in the prevention of the intraocular pressure spike after Nd : YAG laser posterior capsulotomy. Curr Eye Res. 2002 Oct;25(4):237-41. doi: 10.1076/ceyr.25.4.237.13484. (PubMed ID 12658557)
3. Migliazzo CV, Hagan JC 3rd: Beta blocker eye drops for treatment of acute migraine. Mo Med. 2014 Jul-Aug;111(4):283-8. (PubMed ID 25211851)
4. Leier CV, Baker ND, Weber PA: Cardiovascular effects of ophthalmic timolol. Ann Intern Med. 1986 Feb;104(2):197-9. doi: 10.7326/0003-4819-104-2-197. (PubMed ID 3946944)
5. Valvo E, Gammaro L, Tessitore N, Fabris A, Ortalda V, Bedogna V, Maschio G: Effects of timolol on blood pressure, systemic hemodynamics, plasma renin activity, and glomerular filtration rate in patients with essential hypertension. Int J Clin Pharmacol Ther Toxicol. 1984 Mar;22(3):156-61. (PubMed ID 6370874)
6. Matuszewski, B. K.; Constanzer, M. L.; Woolf, E. J.; Au, T.; Haddix, H.: J. Chromatogr. B. 653, 77 (1994)
7. Constanzer, M. L.; Chavez, C. M.; Matuszewski, B. K.: J. Pharm. Biomed. Anal. 15, 1001 (1997)
8. Satuf, M. L.; Robles, J. C.; Goicoechea, H. C.; Oliveri, A. C.: Anal. Lett. 32, 2019 (1999)
9. Tim, R. C.; Kautz, R. A.; Karger, B. L.; Electrophoresis 21, 220 (2000)
10. Carlin, J. R.; Walkar, R. W.; Davies, R. O.; Ferguson, R. K.; Vandenheuvel, W. J. A.: J. Pharm. Sci. 69, 1111 (1980)
11. Lennard M. S.; Parkin, S.: J. Chromatogr. B. 338, 249 (1985)
12. Kubota, K.; Nakamura, H.; Koyama, E.; Yamada, T.; Kikuchi, K.; Ishizaki, T.: J. Chromatogr. B. 533, 255 (1990)
13. Kulkarni, S. P.; Amin, P. D.: J. Pharm. Biomed. Anal. 23, 983 (2000)
14. Erk, N.: J. Pharm. Biomed. Anal. 28, 391 (2002)
15. Bebawy, L. I.: J. Pharm. Biomed. Anal. 27, 737 (2002)
16. Patel, B. R.; Krischbaum J. J.; Poet, R. B.: J. Pharm. Sci. 70, 336 (1981)
17. Mazzo D. J.; Snyder, P. A.: J. Chromatogr. 438, 85 (1988)
18. Mazzo, D. J.: J. Chromatogr. 299, 503 (1984)